Anticipated difficult airway with limited resources
ED discharge criteria and follow up
Discharge suitability
Clinical stability after therapy
Work of breathing near baseline
SpO2 at target on baseline oxygen or room air
Home supports adequate
Ability to obtain medications and devices
Caregiver support if frail
No concerning alternate diagnosis
No ischemic symptoms requiring workup
No imaging or exam suggesting pneumonia requiring admission
Follow up plan
Primary care or respirology follow up
Within 2 to 7 days if moderate exacerbation
Earlier if frequent exacerbator phenotype
Smoking cessation and vaccination update
Influenza and pneumococcal status review
Pulmonary rehabilitation referral when appropriate
Treatment
Oxygen and ventilatory support
Respiratory support strategy
Controlled oxygen
SpO2 target 88% to 92%
Venturi mask for precise FiO2 when needed
Noninvasive ventilation
Indications
pH 7.25 to 7.35 with elevated PaCO2
Severe dyspnea with accessory muscle use
Initial settings example
IPAP 10 to 15 cmH2O
EPAP 4 to 6 cmH2O
Titration targets
Reduced work of breathing
Improving pH and PaCO2 within 1 to 2 hours
Contraindications
Inability to protect airway
Hemodynamic instability
Intubation and invasive ventilation
Indications
NIV failure with worsening acidosis
Refractory hypoxemia
Ventilation principles
Low respiratory rate with prolonged expiratory time
Permissive hypercapnia with pH tolerance individualized
Bronchodilators
Short acting bronchodilator regimen
Salbutamol nebulized
2.5 to 5 mg every 20 minutes for 3 doses
Then every 1 to 4 hours as needed
Ipratropium nebulized
0.5 mg every 20 minutes for 3 doses
Then every 4 to 6 hours
Metered dose inhaler alternative
Salbutamol 4 to 8 puffs via spacer
Ipratropium 4 to 8 puffs via spacer
Adverse effect monitoring
Tachycardia and tremor
Hypokalemia risk with high dose beta agonist
Systemic corticosteroids
Steroid therapy
Prednisone oral
40 mg daily
Typical duration 5 days
Methylprednisolone IV alternative
40 mg IV daily when unable to take oral
Transition to oral when feasible
Key effects
Improved FEV1 and dyspnea
Reduced treatment failure and relapse
Safety considerations
Hyperglycemia monitoring
Delirium risk in older adults
Antibiotics
Antibiotic decision framework
Indications consistent with bacterial trigger
Increased sputum purulence
Increased sputum volume
Increased dyspnea
Ventilation related indication
NIV requirement
Intubation requirement
Outpatient regimen examples
Amoxicillin clavulanate
875 mg orally twice daily
Duration 5 to 7 days
Doxycycline
100 mg orally twice daily
Duration 5 to 7 days
Azithromycin
500 mg orally once then 250 mg daily
Duration 5 days
Inpatient regimen considerations
Ceftriaxone plus azithromycin if pneumonia overlap
Antipseudomonal coverage if risk factors present
Risk factors for Pseudomonas
Bronchiectasis
Prior Pseudomonas culture
Recent broad spectrum antibiotics
Adjuncts and special therapies
Additional therapies
Magnesium sulfate IV
Not routine for COPD
Consider only if strong asthma overlap phenotype
Mucolytics and airway clearance
Hydration and expectoration support
Physiotherapy if copious secretions
Diuretics
If clear heart failure overlap
Avoid empiric diuresis without supportive findings
Venous thromboembolism prophylaxis
Pharmacologic prophylaxis for admitted patients unless contraindicated
Mechanical prophylaxis if bleeding risk
Evidence levels and guideline alignment
Guideline and evidence notes
Systemic corticosteroids and short acting bronchodilators core therapy
Class I recommendation in major COPD guidelines
Reduced relapse and improved lung function
Noninvasive ventilation for acute hypercapnic respiratory failure
Class I recommendation in ATS ERS guidance
Reduced need for intubation and mortality
Antibiotics when increased sputum purulence plus other symptoms or ventilation required
Guideline supported
Benefit greatest in severe exacerbations
ACEP evidence labeling usage note
ED COPD specific ACEP Level A B C varies by topic
Use local ED pathways for formal ACEP linkage when available
Special Populations
Pregnancy
Pregnancy considerations
Maternal oxygenation priority
SpO2 target at least 95% if fetal concerns
Balance with hypercapnia risk using blood gas reassessment
Medication safety
Short acting bronchodilators acceptable
Systemic steroids acceptable when needed
Imaging and PE assessment
VTE risk increased in pregnancy
Radiation minimizing pathway per local protocol
Geriatric
Older adult considerations
Delirium risk
Hypercapnia and hypoxemia contribution
Steroid related agitation
Comorbidity overlap
Heart failure and pneumonia common
Polypharmacy including sedatives
Disposition threshold lower
Frailty and poor reserve
Need for close follow up and home supports
Pediatrics
Pediatric considerations
True COPD rare
Alternate diagnosis more likely
Asthma and bronchiolitis common
If known early onset obstructive disease
Cystic fibrosis bronchiectasis overlap
Congenital airway disorders
Weight based dosing requirement
Nebulized bronchodilators by weight
Early pediatric consultation
Background
Epidemiology
Epidemiology highlights
COPD definition
Persistent airflow limitation with chronic respiratory symptoms
SNOMED CT term chronic obstructive lung disease
Exacerbation impact
Accelerated lung function decline
Increased mortality risk after severe exacerbation
Common ICD-10 coding
COPD with acute exacerbation ICD-10 J44.1
Acute respiratory failure with hypercapnia ICD-10 J96.02
Pathophysiology
Pathophysiologic mechanisms
Bronchial inflammation and mucus
Increased airway resistance
Mucus plugging and atelectasis risk
Emphysema and loss of elastic recoil
Air trapping and hyperinflation
Reduced inspiratory capacity
Gas exchange abnormalities
VQ mismatch driving hypoxemia
Hypoventilation driving hypercapnia
Therapeutic Considerations
Therapy rationale
Short acting bronchodilators
Bronchospasm reduction
Improved expiratory flow and symptom relief
Systemic steroids
Reduced airway inflammation
Shorter recovery and reduced relapse
Antibiotics in selected patients
Bacterial load reduction
Prevent treatment failure in severe cases
Noninvasive ventilation
Reduced work of breathing
Improved alveolar ventilation and pH
Patient Discharge Instructions
copy discharge instructions
Discharge instructions for COPD flare
Medication plan
Rescue inhaler use as prescribed
Steroid course completion if prescribed
Antibiotic plan if prescribed
Complete full course
Diarrhea or rash prompt medical advice
Oxygen guidance
Use oxygen as prescribed
Target saturation plan if provided
Activity and recovery
Gradual return to normal activity
Hydration and airway clearance measures
Follow up
Primary care or respirology within 2 to 7 days
Inhaler technique review at follow up
Return to ED immediately if
Severe shortness of breath at rest
Blue lips or fingers
Confusion or extreme sleepiness
Chest pain or fainting
SpO2 below target despite usual oxygen
Unable to speak in full sentences
Prevention
Smoking cessation support
Vaccination discussion at follow up
Pulmonary rehabilitation discussion when stable
References
Clinical guidelines and evidence sources
Global Initiative for Chronic Obstructive Lung Disease COPD report
Exacerbation diagnosis and severity assessment guidance
Pharmacologic and ventilatory management recommendations
ATS ERS clinical practice guideline on noninvasive ventilation for acute respiratory failure
NIV indications for COPD with hypercapnic acidosis
NIV outcomes including reduced intubation and mortality
NICE guideline on chronic obstructive pulmonary disease in over 16s
Antibiotic selection guidance for exacerbations
Discharge and follow up recommendations
Cochrane systematic reviews on systemic corticosteroids in AECOPD
Reduced treatment failure and relapse
Adverse effects including hyperglycemia
Cochrane systematic reviews on antibiotics for AECOPD
Benefit in severe exacerbations and ventilated patients
Stewardship considerations
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.